Chemical process research and development in the 21st century: Challenges, strategies, and solutions from a pharmaceutical industry perspective

Accounts of Chemical Research

Volumn 42, Issue 5, 2009, Pages 671-680

  Federsel, Hans Jürgen ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHEMICAL STRUCTURE; DRUG INDUSTRY; METHODOLOGY;

DRUG INDUSTRY; MOLECULAR STRUCTURE; RESEARCH DESIGN;

EID: 66149123969     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar800257v     Document Type: Article

References (51)

1. (a) Repič, O. Principles of Process Research and Chemical Development in the Pharmaceutical Industry, Wiley and Sons: New York, 1998.
2. (b) Process Chemistry in the Pharmaceutical Industry, Gadamasetti, K. G., Ed.; Marcel Dekker: NewYork, 1999.
3. (c) Anderson, N. G. Practical Process Research & Development, Academic Press: San Diego, CA, 2000.
4. (d) Cabri, W.; DiFabio, R. From Bench to Market: The Evolution of Chemical Synthesis; Oxford University Press: Oxford, U.K., 2000.
5. (e) From Bench to Pilot Plant. Process Research in the Pharmaceutical Industry, Nafissi, M.; Ragan, J. A., DeVries, K. M., Eds.; American Chemical Society: Washington, DC, 2002.
6. (f) Federsel, H.-J. Start small, think big - The art of process R&D. Nat. Rev. Drug Discovery 2001, 1 (12), 1013.
7. (g) Federsel, H.-J. Logistics of process R&D: Transforming laboratory methods to manufacturing scale. Nat. Rev. Drug Discovery 2003, 2(8), 654-664.
8. (h) Lipton, M. F.; Barrett, A. G. M., Guest Editors, Process Chemistry, Chem. Rev. 2006, 106 (7), 2581-3027.
9. (i) Rao, C. S. The Chemistry of Process Development in Fine Chemical & Pharmaceutical Industry, 2nd ed.; Wiley & Asian Books Private Ltd.: Chichester and New Delhi, 2006.
10. (j) Process Chemistry in the Pharmaceutical Industry, Vol. 2, Challenges in an Ever Changing Climate; Gadamasetti, K.; Braish, T. F., Eds.; CRC Press: Boca Raton, FL, 2008.
11. (k) Org. Process Res. Dev.; Laird, T., Ed.; this journal is entirely devoted to publishing work from the process R&D arena since 1997; see journal homepage http://pubs.acs.org/journal/oprdfk/.
12. (a) Federsel, H.-J. The integration of process R&D in drug discovery - Challenges and opportunities. Comb. Chem. High Throughout Screening 2006, 9(2), 79-86.
13. (b) Comprehensive Medicinal Chemistry II, Vol. 2, Strategy and Drug Research; Moos, W. H., Ed.; Elsevier: Oxford, U.K., 2007.
14. (c) Woodcock, J.; Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med 2008, 59, 1-12.
15. (d) Federsel, H.-J. Handing over the baton: Connecting medicinal chemistry with process R&D. Drug News Perspect. 2008, 21 (4), 193-199.
16. Federsel, H.-J. Development of a process for a chiral aminochroman antidepressant: A case story. Org. Process Res. Dev. 2000, 4 (5), 362-369.
17. (a) Federsel, H.-J. Drug discoverers - you need us. Drug Discovery Todav 2001, 6 (8), 397-398.
18. (b) Federsel, H.-J. The role of process R&D in drug discovery - Evolution of an interface. Chim. Oggi/Chem. Todav 2004, 22 (3/4), 9-12.
19. (c) Potoski, J. Timely synthetic support for medicinal chemists. Drug Discovery Today 2005, 10 (2), 115-120.
20. Federsel, H.-J. In search of sustainability: Process R&D in light of current pharmaceutical industry challenges. Drug Discovery Today 2006, 11 (21/22), 966-974.
21. Carey, J. S.; Laffan, D.; Thomson, C.; Williams, M. T. Analysis of the reactions used for the preparation of drug candidate molecules. Org. Biomol. Chem. 2006, 4(12), 2337-2347.
22. (a) Federsel, H.-J. Drug chirality - scale-up manufacturing, and control. CHEMTECH 1993, 23 (12), 24-33.
23. (b) Federsel, H.-J. Facing chirality in the 21st century: Approaching the challenges in the pharmaceutical industry. Chirality 2003, 15 (S1), S128-S142.
24. (c) Federsel, H.-J. Searching for scalable processes: Addressing the challenge in times of increasing complexity. Curr. Opin. Drug Discovery Dev. 2003, 6(6), 838-847.
25. (d) Breuer, M.; Ditrich, K.; Habicher, T.; Hauer, B.; Kesseler, M.; Stürmer, R.; Zelinski, T. Industrial methods for the production of optically active intermediates. Angew. Chem., Int. Ed. 2004, 43(1), 788-824.
26. (e) Federsel, H.-J. Chiral Drug Discovery and Development - From Concept Stage to Market Launch. Comprehensive Medicinal Chemistry II, Vol. 2, Strategy and Drug Research; Moos, W. H., Ed.; Elsevier: Oxford, U.K., 2007; Chapter 2.17, pp 713-736.
27. (a) Blaser, H.-U.; Spindler, F.; Studer, M. Enantioselective catalysis in fine chemicals production. APPL. Catal. A 2001, 221 (1-2), 119-143.,
28. (b) Federsel, H.-J. Asymmetry on large scale: The roadmap to stereoselective processes. Nat. Rev. Drug Discovery 2005, 4 (8), 685-697.
29. (c) Asymmetric Catalysis on Industrial Scale. Challenges, Approaches and Solutions; Blaser, H.-U., Schmidt, E., Eds.; Wiley-VCH: Weinheim, Germany, 2004.
30. (d) Blaser, H.-U.; Pugin, B.; Spindler, F. Progress in enantioselective catalysis assessed from an industrial point of view. J. Mol. Catal. A: Chem. 2005, 231 (1-2), 1-20.
31. (e) Federsel, H.-J. Stereoselective Synthesis of Drugs - An Industrial Perspective. In Chirality in Drug Research; Francotte, E., Lindner, W., Eds.; Wiley-VCH: Weinheim, Germany, 2006; Chapter 2, pp 29-65.
32. (a) Blaser, H.-U. The chiral switch of (S)-metolachlor: A personal account of an industrial Odyssey in asymmetric catalysis. Adv. Synth. Catal. 2002, 344 (1), 17-31.
33. (b) Blaser, H.-U.; Hanreich, R.; Schneider, H.-D.; Spindler, F.; Steinacher, B. The chiral switch of metolachlor: The development of a large-scale enantioselective catalytic process. Asymmetric Catalysis on Industrial Scale. Challenges, Approaches and Solutions; Blaser, H.-U., Schmidt, E., Eds.; Wiley-VCH: Weinheim, Germany, 2004, pp 55-70.
34. (a) Federsel, H.-J.; Larsson, M. An Innovative Asymmetric Sulfide Oxidation: The Process Development History Behind the New Antiulcer Agent Esomeprazole. Asymmetric Catalysis on Industrial Scale. Challenges, Approaches and Solutions; Blaser, H.-U., Schmidt, E., Eds.; Wiley-VCH: Weinheim, Germany, 2004, pp 413-436.
35. (b) Seenivasaperumal, M.; Federsel, H.-J.; Ertan, A.; Szabó, K. J. Factors influencing the selectivity in asymmetric oxidation of sulfides attached to nitrogen containing heterocycles. Chem. Commun. 2007, 2187-2189.,
36. (c) Seenivasaperumal, M.; Federsel, H.-J.; Szabó, K. J. Mechanism of the asymmetric sulfoxidation in the esomeprazole process. Effects of the imidazole backbone for the enantioselection. Adv. Synth. Catal. 2009, in press.
37. George, M.; Rowlands, D.; Kastle, B. What is lean six sigma? McGraw-Hill: New York, 2004.
38. Sewing, A.; Winchester, T.; Carnell, P.; Hampton, D.; Keighley, W. Helping science to succeed: Improving processes in R&D. Drug Discovery Today 2008, 13 (5/6), 227-233.
39. Romañach, R. J. Research initiatives to support science-based pharmaceutical manufacturing. Pharm. Technol. Eur. 2007, 19 (10), 47-51.
40. Butters, M.; Catterick, D.; Craig, A.; Curzons, A.; Dale, D.; Gillmore, A.; Green, S. P.; Marziano, I.; Sherlock, J.-P.; White, W. Critical assessment of pharmaceutical processes - A rationale for changing the synthetic route. Chem. Rev. 2006, 106 (7), 3002-3027.
41. Anastas, P. T.; Kirchhoff, M. M. Origins, current status, and future challenges of green chemistry. Acc. Chem. Res. 2002, 35 (9), 686-694.
42. (a) Trost, B. M. The atom economy - a search for synthetic efficiency. Science 1991, 254 (5037), 1471-1477.
43. (b) Trost, B. M. On inventing reactions for atom economy. Acc. Chem. Res. 2002, 35 (9), 695-705.
44. (a) Anastas, P. T.; Zimmerman, J. B. The twelve principles of green engineering as a foundation for sustainability. In Sustainability Science and Engineering Volume 1: Defining principles; Abraham, M. A., Ed.; Elsevier: Amsterdam, 2006; Vol 1, Chapter 2, pp 11-32.
45. (b) Mours, M. SusChem: From vision to action. ChemSusChem 2008, 1 (1/2), 59-62.
46. Federsel, H.-J.; Sveno, A. To overcome the hurdles: coping with the synthesis of robalzotan, a complex chroman antidepressant. Process Chemistry in the Pharmaceutical Industry, Vol. 2, Challenges in an Ever Changing Climate; Gadamasetti, K.; Braish, T. F., Eds.; CRC Press: Boca Raton, FL, 2008; Chapter 7, pp 111-135.
47. Fuchs, P. L. Increase in intricacy - a tool for evaluating organic syntheses. Tetrahedron 2001, 57 (32), 6855-6875.
48. Wiles, C.; Watts, P. Continuous flow reactors, a tool for the modern synthetic chemist. Eur. J. Org. Chem. 2008, 1655-1671.
49. Ainge, D.; Ennis, D.; Gidlund, M.; Stefinovic, M.; Vaz, L.-M. Rapid development of an enantioselective synthesis of (R)-1-hydroxy-7-methoxy- 1,2,3,4-tetrahvdronaDhthalene-1-carboxvlic acid. Org. Process Res. Dev. 2003, 7(2), 198-201.
50. Grubb, P. W. Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy Oxford University Press: Oxford, U.K., 2005.
51. Seibert, K. D.; Sethuraman, S.; Mitchell, J. D.; Griffiths, K. L.; McGarvey, B. The use of routine process capability for the determination of process parameter criticality in small-molecule API synthesis. J. Pharm. Innovation 2008, 3, 105-112.